For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit

Our Network

Our network encompasses an elite group of professionals carefully selected based on their expertise in business formation and operations, as well as for their desire and ability to effectively share hard-earned lessons with our program participants.

  • Office Hours - Our director is available to answer any questions and refer inventors to additional resources.

  • Entrepreneurs in Residence - Our network of industry professionals provide their expertise to help translate your discoveries.  After an initial meeting with the director, you may be referred to one of these advisors who may be able to offer his or her help in the specific industry or functional domain.

See below for more information.

Click here for more information.

BioPharma Alliances and Research Collaborations

  • Larry Schlossman, Managing Director
  • Jessica Tabankin, Director of Operations and Portfolio Management
  • Jill Gold, Director, BioPharma Transactions
  • Suzanne Mueller, Director, Business and Operations Associate

BioVenture eLab Team

Jahan Ali, PhD, is the Director of Bioventure eLab at Weill Cornell Medical Center. Formerly, she founded and led Octane Ventures, a venture catalyst firm that works with nonprofits, universities and small biotech/health-tech companies on strategic advice, licensing and operational assistance. Dr. Ali was also a Director of Business Development at International AIDS Vaccine Initiative, where she worked with vaccine and antibody development teams. Dr. Ali brings a unique perspective to the biotech space, gained from being on multiple sides of early stage technology in technology commercialization at Mount Sinai School of Medicine and Hospital for Special Surgery and led the healthcare investments for the Partnership Fund, an investment fund founded by Henry Kravis. She has mentored numerous early stage companies, through ELabNYC and Springboard Enterprises; and is adept is building relationships with multiple stakeholders.

Connor Dowling is the Chief Operating Officer in the BioVenture eLab and joined the eLab at inception in 2016. Prior to joining Weill Cornell Medicine, Connor helped start a logistics technology platform in the trucking space. Serving as Manager of Product and Operations, he focused on product management, business development in the freight broker/shipper space, and operations. The company won Carnegie Mellon University’s McGinnis Venture Competition and was selected to participate in the Entrepreneurs Roundtable Accelerator, a leading New York City technology incubator.

Connor previously co-founded the Miss Kate Foundation, a non-profit focused on fundraising for brain cancer research; the foundation's events have been attended by 800+ people in New York City. He began his career at the U.S. Chamber of Commerce, the world's largest business federation, in the Capital Markets Division in Washington D.C. In his free time, Connor is also the founder of a popular digital travel magazine with over 15,000 subscribers. Connor graduated with a degree in Business and Management from Skidmore College where he was an All-Conference lacrosse player.

Loren Busby, CFA, MBA is the BioVenture eLab Entrepreneur in Residence. Ms. Busby is President of Cresco Advisors where she serves as an Entrepreneur in Residence and business advisor to portfolio companies. She currently works with several technology businesses operating at the intersection of artificial intelligence and healthcare as well as life science tools companies. She is also a co-founder of Life Science Vendor Expo, a conference series providing entrepreneurs with educational workshops that address some of their operating challenges. She has over two decades of experience in VC and was “one of the 6%,” referring to the exclusive group of female investment professionals. She was a Partner at NGN Capital, a transatlantic, healthcare fund where she invested in healthcare IT companies and participated in deals in the therapeutics and medical device sectors. Ms. Busby joined NGN Capital from Walden Capital Partners, which invested in the technology, manufacturing and distribution industries. In the mid-1990s, Ms. Busby worked at Princeton University’s endowment on its alternative asset portfolio. She began her career at Venture Economics and Thomson Financial, which at the time published the venerable Venture Capital Journal. From 2005-2009, Ms. Busby was a leader of CFA Society of New York’s Alternative Investments Committee, which had 450 members. She is a Chartered Financial Analyst and also earned an M.B.A. from Columbia University as a McCain Scholar and a B.S. from Central Connecticut State University.